Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1757607rdf:typepubmed:Citationlld:pubmed
pubmed-article:1757607lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0013072lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0098735lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0750848lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0406317lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0028912lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0392752lld:lifeskim
pubmed-article:1757607lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:1757607pubmed:issue6 Pt 2lld:pubmed
pubmed-article:1757607pubmed:dateCreated1992-2-4lld:pubmed
pubmed-article:1757607pubmed:abstractTextIn a double-blind, parallel-group, multicenter comparative trial in 84 evaluable patients with severe, localized plaque psoriasis, 0.05% halobetasol propionate ointment proved significantly superior (p = 0.02) to 0.1% betamethasone valerate ointment with respect to the success rate, as indicated by ratings of "healed" or "marked improvement" (88.1% versus 64.3%). The therapeutic effect was observed within 5 days of the start of treatment in 76% and 67% of the patients treated with halobetasol propionate and betamethasone valerate ointments, respectively. Both preparations were well tolerated. Minor adverse effects at the site of application were reported in only 2% of the patients in each treatment group. Neither skin atrophy nor systemic adverse effects were observed.lld:pubmed
pubmed-article:1757607pubmed:languageenglld:pubmed
pubmed-article:1757607pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757607pubmed:citationSubsetIMlld:pubmed
pubmed-article:1757607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757607pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757607pubmed:statusMEDLINElld:pubmed
pubmed-article:1757607pubmed:monthDeclld:pubmed
pubmed-article:1757607pubmed:issn0190-9622lld:pubmed
pubmed-article:1757607pubmed:authorpubmed-author:BlumGGlld:pubmed
pubmed-article:1757607pubmed:authorpubmed-author:YawalkarSSlld:pubmed
pubmed-article:1757607pubmed:issnTypePrintlld:pubmed
pubmed-article:1757607pubmed:volume25lld:pubmed
pubmed-article:1757607pubmed:ownerNLMlld:pubmed
pubmed-article:1757607pubmed:authorsCompleteYlld:pubmed
pubmed-article:1757607pubmed:pagination1153-6lld:pubmed
pubmed-article:1757607pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:meshHeadingpubmed-meshheading:1757607-...lld:pubmed
pubmed-article:1757607pubmed:year1991lld:pubmed
pubmed-article:1757607pubmed:articleTitleA comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis.lld:pubmed
pubmed-article:1757607pubmed:affiliationHôpital Cantonal, Fribourg, Switzerland.lld:pubmed
pubmed-article:1757607pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1757607pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1757607pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1757607pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:1757607pubmed:publicationTypeControlled Clinical Triallld:pubmed
pubmed-article:1757607pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:1757607pubmed:publicationTypeMulticenter Studylld:pubmed